Celldex Therapeutics, Inc. (CLDX) On The Rise

Page 2 of 2

Iclusig revenue is still on the low side as it hasn’t sold for long, but Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) says that Iclusig had made $6.4 million in its first launch quarter. Still Iclusig will be responsible for a big pipeline in the future. I say this because Iclusig will be used to target other cancers like Acute Myeloid Leukemia, Lung cancer, Gastrointestinal tumors, and other indications of Chronic Myeloid Leukemia. The whole pipeline is worth in the billions, and I think that it can go higher.

Final Thought

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has a growing pipeline, that will continue to grow over the years. After many good results the company continues to advance into many cancer therapeutic areas. Although it has a lot going for itself, it has to deal with a lot of other biotech companies with upcoming cancer therapies that could prove to be more efficacious in nature. Celldex should continue to be valued higher as more analysts learn about the trials, and realize the market potential that it is targeting. I would do some due diligence on this company, and accumulate for the long term.

Terry Chrisomalis has no position in any stocks mentioned. The Motley Fool recommends Seattle Genetics.

The article Celldex On The Rise originally appeared on Fool.com and is written by Terry Chrisomalis.

Terry is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2